Douglas Maffei | IR |
Daniel O'Day | Chairman and CEO |
Andrew Dickinson | CFO |
Johanna Mercier | Chief Commercial Officer |
Merdad Parsey | Chief Medical Officer |
Christi Shaw | CEO, Kite |
Diana Brainard | SVP and Head, HIV and Emerging Viruses Therapeutic |
Michael Yee | Jefferies |
Brian Abrahams | RBC Capital Markets |
Geoff Meacham | Bank of America |
Geoffrey Porges | SVBLeerink |
Matthew Harrison | Morgan Stanley |
Umer Raffat | Evercore ISI |
Cory Kasimov | JP Morgan |
Mohit Bansal | Citi |
Alethia Young | Cantor Fitzgerald |
Salim Syed | Mizuho |
Phil Nadeau | Cowen and Company |
Ladies and gentlemen, thank you for standing by. And welcome to the Gilead Sciences Fourth Quarter 2019 Earnings Conference Call. My name is Liz, and I will be your operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded.